drugset / Trial / NCT07083349
NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus
Phase 0
Terminated
4 enrolled
Base Therapeutics (Shanghai) Co., Ltd.
The First Affiliated Hospital of Anhui Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated, open-label, single-arm study to determine safety and preliminary efficacy of NK510 for the treatment of patients with refractory systemic lupus erythematosus (SLE) in China.
Timeline
- Start
- 2025-12-01
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
Outcome
Outcome not reported
Stopped (Enrollment): “poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NK510 | Cell therapy | 4e+07 cells/kg | Intravenous |
| Subject | NK510 | Cell therapy | 8e+07 cells/kg | Intravenous |
| Subject | NK510 | Cell therapy | 1.2e+08 cells/kg | Intravenous |